The global market for Plasma Apheresis Machines was valued at US$13.1 Billion in 2025 and is projected to reach US$25.4 Billion by 2032, growing at a CAGR of 9.9% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
Therapeutically, plasma apheresis (or plasmapheresis) is used in the treatment of conditions such as myasthenia gravis, thrombotic thrombocytopenic purpura (TTP), Guillain-Barre syndrome, and lupus. It helps remove pathogenic autoantibodies, immune complexes, or excess proteins from circulation. In donor settings, these machines allow for the collection of high-purity plasma while returning other blood components-minimizing donor fatigue and enabling higher collection frequency. This operational efficiency is critical for biopharmaceutical manufacturers relying on plasma fractionation to produce life-saving biologics.
The COVID-19 pandemic also brought renewed attention to convalescent plasma therapy, temporarily driving up demand for plasma apheresis systems in hospitals and blood centers. Even as such therapies are phased out, the event underscored the strategic importance of scalable and efficient plasma collection infrastructure.
Membrane filtration-based devices, though less common than centrifugal models, are gaining interest for selective plasma removal (e.g., therapeutic plasma exchange without cellular loss). These machines are increasingly used in pediatric care, intensive care units, and niche hematology applications. Dual needle access, disposable kits with closed-loop tubing, and RFID-enabled component tracking are now standard features across leading models-ensuring infection control and patient traceability.
Software upgrades are also enabling remote diagnostics, data capture, and integration with hospital EMR systems. AI-based flow optimization, automated pressure balancing, and personalized treatment algorithms are being incorporated into clinical settings to reduce procedure times and improve patient comfort. These advances are not only improving clinical outcomes but also optimizing workflow in high-throughput donation centers.
In Europe, Germany, Austria, and the UK lead clinical use, particularly in autoimmune and nephrology centers. In Asia-Pacific, Japan, South Korea, and China are seeing increasing equipment procurement, both for therapeutic applications and to support domestic plasma fractionation. India, while still emerging, has seen a surge in demand driven by rising autoimmune disease prevalence and expanded private hospital infrastructure.
Hospital settings dominate therapeutic apheresis deployment, while donor centers, mobile blood units, and standalone plasma banks represent the bulk of equipment demand for collection. The growing focus on personalized medicine, rising incidences of rare immunological disorders, and expansion of blood transfusion networks in emerging markets are contributing to broader system adoption across diverse healthcare environments.
Technological enhancements in separation efficiency, donor comfort, and infection control are making apheresis more accessible and scalable. Biopharma expansion into plasma-derived product manufacturing is prompting private investments into donor centers and blood collection modernization, particularly in the U.S., China, and Latin America. Furthermore, favorable reimbursement frameworks, rising prevalence of neurological and hematological disorders, and increased government focus on self-sufficiency in plasma supply are fueling procurement of advanced apheresis devices.
With the convergence of clinical demand, regulatory support, and industry innovation, plasma apheresis machines are no longer niche medical equipment-they are vital components in modern transfusion medicine and personalized therapy ecosystems. Their global relevance is set to rise as plasma therapeutics and autoimmune disease management gain further traction.
Global Plasma Apheresis Machines Market - Key Trends & Drivers Summarized
Why Are Plasma Apheresis Machines Becoming Indispensable in Therapeutic and Donor Applications?
Plasma apheresis machines-critical devices that separate plasma from whole blood-are increasingly being deployed across donor centers, transfusion medicine, and clinical therapy settings. These machines enable both autologous plasma exchange and donor plasma collection, playing a vital role in managing autoimmune diseases, hematological disorders, and plasma protein therapies. As global demand for immunoglobulins, albumin, clotting factors, and convalescent plasma rises, plasma apheresis systems are becoming the cornerstone of the plasma-derived therapeutics value chain.Therapeutically, plasma apheresis (or plasmapheresis) is used in the treatment of conditions such as myasthenia gravis, thrombotic thrombocytopenic purpura (TTP), Guillain-Barre syndrome, and lupus. It helps remove pathogenic autoantibodies, immune complexes, or excess proteins from circulation. In donor settings, these machines allow for the collection of high-purity plasma while returning other blood components-minimizing donor fatigue and enabling higher collection frequency. This operational efficiency is critical for biopharmaceutical manufacturers relying on plasma fractionation to produce life-saving biologics.
The COVID-19 pandemic also brought renewed attention to convalescent plasma therapy, temporarily driving up demand for plasma apheresis systems in hospitals and blood centers. Even as such therapies are phased out, the event underscored the strategic importance of scalable and efficient plasma collection infrastructure.
What Technological Advances Are Enhancing Efficacy and Patient Safety in Apheresis Procedures?
The design and performance of plasma apheresis machines have undergone substantial innovation over the past decade. Modern systems use automated centrifugal or membrane-based separation techniques governed by precise software-controlled flow rates, anticoagulant dosing, and real-time monitoring. Brands such as Terumo BCT (Trima Accel), Fresenius Kabi (Amicus), and Haemonetics have launched next-generation machines with enhanced throughput, user-friendly interfaces, and integrated safety alerts.Membrane filtration-based devices, though less common than centrifugal models, are gaining interest for selective plasma removal (e.g., therapeutic plasma exchange without cellular loss). These machines are increasingly used in pediatric care, intensive care units, and niche hematology applications. Dual needle access, disposable kits with closed-loop tubing, and RFID-enabled component tracking are now standard features across leading models-ensuring infection control and patient traceability.
Software upgrades are also enabling remote diagnostics, data capture, and integration with hospital EMR systems. AI-based flow optimization, automated pressure balancing, and personalized treatment algorithms are being incorporated into clinical settings to reduce procedure times and improve patient comfort. These advances are not only improving clinical outcomes but also optimizing workflow in high-throughput donation centers.
Which Clinical Settings and Regional Markets Are Accelerating Equipment Deployment?
The plasma apheresis market is highly active in North America, Europe, and select Asian countries where both donation and therapeutic applications are well established. The U.S. is the single largest market, supported by a vast network of commercial plasma donation centers operated by companies like CSL Plasma, Grifols, and Octapharma. These centers require highly reliable apheresis machines capable of operating under high daily volumes with minimal maintenance downtime.In Europe, Germany, Austria, and the UK lead clinical use, particularly in autoimmune and nephrology centers. In Asia-Pacific, Japan, South Korea, and China are seeing increasing equipment procurement, both for therapeutic applications and to support domestic plasma fractionation. India, while still emerging, has seen a surge in demand driven by rising autoimmune disease prevalence and expanded private hospital infrastructure.
Hospital settings dominate therapeutic apheresis deployment, while donor centers, mobile blood units, and standalone plasma banks represent the bulk of equipment demand for collection. The growing focus on personalized medicine, rising incidences of rare immunological disorders, and expansion of blood transfusion networks in emerging markets are contributing to broader system adoption across diverse healthcare environments.
What Is Driving Growth in the Global Plasma Apheresis Machines Market?
The growth in the global plasma apheresis machines market is driven by increasing demand for plasma-derived biologics, expansion of donor plasma collection infrastructure, and broader adoption of therapeutic apheresis in clinical protocols. As healthcare systems recognize the importance of plasma-based treatments in managing chronic and autoimmune conditions, the need for efficient and safe apheresis machines continues to grow.Technological enhancements in separation efficiency, donor comfort, and infection control are making apheresis more accessible and scalable. Biopharma expansion into plasma-derived product manufacturing is prompting private investments into donor centers and blood collection modernization, particularly in the U.S., China, and Latin America. Furthermore, favorable reimbursement frameworks, rising prevalence of neurological and hematological disorders, and increased government focus on self-sufficiency in plasma supply are fueling procurement of advanced apheresis devices.
With the convergence of clinical demand, regulatory support, and industry innovation, plasma apheresis machines are no longer niche medical equipment-they are vital components in modern transfusion medicine and personalized therapy ecosystems. Their global relevance is set to rise as plasma therapeutics and autoimmune disease management gain further traction.
Report Scope
The report analyzes the Plasma Apheresis Machines market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:- Segments: Product Type (Plasma Collection System, Multi-Component Collection System); Application (Extracorporeal Therapy Application, Plasma Donation Application)
- Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Plasma Collection System segment, which is expected to reach US$17.5 Billion by 2032 with a CAGR of a 11.5%. The Multi-Component Collection System segment is also set to grow at 6.8% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $3.6 Billion in 2025, and China, forecasted to grow at an impressive 15.2% CAGR to reach $6.0 Billion by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Plasma Apheresis Machines Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Plasma Apheresis Machines Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Plasma Apheresis Machines Market expected to evolve by 2032?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2032?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Asahi Kasei Medical, B. Braun Melsungen AG, Baxter International, Cerner Corporation, Cerus Corporation and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the companies featured in this Plasma Apheresis Machines market report include:
- Asahi Kasei Medical
- B. Braun Melsungen AG
- Baxter International
- Cerner Corporation
- Cerus Corporation
- Fresenius Kabi
- Haemonetics Corporation
- Haier Biomedical
- HemaCare (Charles River)
- Kaneka Corporation
- Kawasumi Laboratories
- MacoPharma
- Medica S.p.A.
- Miltenyi Biotec
- Nikkiso Co., Ltd.
- Nigale Corporation
- Scinomed
- Shanghai Dahua Medical
- Terumo BCT
- Thermo Fisher Scientific
What Sets This Report Apart From Others?
- Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
- Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
- Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
- Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
- Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
- Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, the report extends market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Asahi Kasei Medical
- B. Braun Melsungen AG
- Baxter International
- Cerner Corporation
- Cerus Corporation
- Fresenius Kabi
- Haemonetics Corporation
- Haier Biomedical
- HemaCare (Charles River)
- Kaneka Corporation
- Kawasumi Laboratories
- MacoPharma
- Medica S.p.A.
- Miltenyi Biotec
- Nikkiso Co., Ltd.
- Nigale Corporation
- Scinomed
- Shanghai Dahua Medical
- Terumo BCT
- Thermo Fisher Scientific
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 273 |
| Published | November 2026 |
| Forecast Period | 2025 - 2032 |
| Estimated Market Value ( USD | $ 13.1 Billion |
| Forecasted Market Value ( USD | $ 25.4 Billion |
| Compound Annual Growth Rate | 9.9% |
| Regions Covered | Global |
